Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer.

Trial Profile

Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2012

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary)
  • Indications Renal cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 25 Feb 2012 Planned end date changed from 22 Sep 2013 to 22 Mar 2015 as reported by EudraCT.
    • 25 Feb 2012 Investigational drug 'Everolimus' identified as reported by EudraCT.
    • 25 Feb 2012 Official title amended as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top